NO20055490L - Risperidon monohydroklorid - Google Patents

Risperidon monohydroklorid

Info

Publication number
NO20055490L
NO20055490L NO20055490A NO20055490A NO20055490L NO 20055490 L NO20055490 L NO 20055490L NO 20055490 A NO20055490 A NO 20055490A NO 20055490 A NO20055490 A NO 20055490A NO 20055490 L NO20055490 L NO 20055490L
Authority
NO
Norway
Prior art keywords
risperidone
monohydrochloride
salts
hemipentahydrate
monohydric
Prior art date
Application number
NO20055490A
Other languages
English (en)
Other versions
NO20055490D0 (no
Inventor
Jiri Bartl
Reinerus Gerardus Gieling
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of NO20055490D0 publication Critical patent/NO20055490D0/no
Publication of NO20055490L publication Critical patent/NO20055490L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Hydrokloridsalter av risperidon har blitt fimnet å ha nyttige egensk^er. En foretrukket form er krystallinsk risperidonmo-nohydrokloridhemipentahydrat. Monohy(^okloridsaltene kan anvendes i farmasøytiske sammensetninger og fremgangsmåter så som for anvendelse i å behandle psykotiske forstyrrelser.
NO20055490A 2003-04-22 2005-11-21 Risperidon monohydroklorid NO20055490L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46436403P 2003-04-22 2003-04-22
PCT/EP2004/004129 WO2004094415A1 (en) 2003-04-22 2004-04-15 Risperidone monohydrochloride

Publications (2)

Publication Number Publication Date
NO20055490D0 NO20055490D0 (no) 2005-11-21
NO20055490L true NO20055490L (no) 2006-01-23

Family

ID=33310877

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20055490A NO20055490L (no) 2003-04-22 2005-11-21 Risperidon monohydroklorid
NO20055485A NO20055485L (no) 2003-04-22 2005-11-21 Vannloselige salter av risperidon

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20055485A NO20055485L (no) 2003-04-22 2005-11-21 Vannloselige salter av risperidon

Country Status (5)

Country Link
US (2) US20040266791A1 (no)
EP (2) EP1615924A1 (no)
AR (2) AR044055A1 (no)
NO (2) NO20055490L (no)
WO (2) WO2004094414A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP2272514A1 (en) * 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
ES2838012T3 (es) * 2009-03-12 2021-07-01 Delpor Inc Dispositivo implantable durante un período largo de tiempo de fármacos
EP3199146B1 (en) 2011-04-25 2019-07-17 Shan Dong Luye Pharmaceutical Co., Ltd. Risperidone sustained release microsphere composition
HUE028159T2 (en) 2011-04-26 2016-12-28 Torrent Pharmaceuticals Ltd Acid addition salts of risperidone and pharmaceutical compositions containing them
US9737605B2 (en) 2013-03-11 2017-08-22 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
WO2016149561A1 (en) * 2015-03-17 2016-09-22 Oak Crest Institute Of Science Subdermal implants for the sustained delivery of water-soluble drugs
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
US4342870A (en) * 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US4443451A (en) * 1981-07-15 1984-04-17 Janssen Pharmaceutica N.V. Bicyclic pyrimidin-5-one derivatives
US4485107A (en) * 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation

Also Published As

Publication number Publication date
AR044054A1 (es) 2005-08-24
WO2004094415A1 (en) 2004-11-04
NO20055485L (no) 2006-01-23
EP1615924A1 (en) 2006-01-18
AR044055A1 (es) 2005-08-24
NO20055490D0 (no) 2005-11-21
WO2004094414A1 (en) 2004-11-04
US20040266791A1 (en) 2004-12-30
US20040266790A1 (en) 2004-12-30
EP1615923A1 (en) 2006-01-18
NO20055485D0 (no) 2005-11-21

Similar Documents

Publication Publication Date Title
NO20055490L (no) Risperidon monohydroklorid
FIC20200014I1 (fi) Fostamatinibi tai fostamatinibin farmaseuttisesti hyväksyttävä suola tai fostamatinibin hydraatti, solvaatti, tai N-oksidi, tai fostamatinibin farmaseuttisesti hyväksyttävä suola, erityisesti fostamatinibi dinatrium, valinnaisesti hydraatin muodossa
RS53342B (en) DERIVATIVES OF PRIVATE AND INHIBITORIES MEK
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
SG149033A1 (en) Heterocyclic inhibitors of mek and methods of use thereof
DE60127863D1 (de) Phenylderivate
NO20070458L (no) Aryl-pyridinderivater som 11-Beta-HSD1 inhibitorer
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
TW200504061A (en) Pyrazolopyridine derivatives
NO20061454L (no) Compounds having CRTH2 antagonist activity
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
NO20070445L (no) Pyrimidinderivater.
ATE542800T1 (de) Kinasehemmer und ihre anwendungsverfahren
MX2011011764A (es) Compuestos de carboxamida y su uso como inhibidores de calpaina.
NO20065873L (no) 3-(4-(2-dihydroisoksazol-3-ylpyridin-5-yl)fenyl)-5-triazol-1-ylmetyloksoazolidin-2-on derivater som MAO inhibitorer i behandlingen av bakterielle infeksjoner
GB0314967D0 (en) Piperazine derivatives
SE0302756D0 (sv) Novel Compounds
DE602006007483D1 (no)
HK1070363A1 (en) Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serineprotease factor xa
WO2009015000A8 (en) Pyrazole urea derivatives used as kinase inhibitors
IL162983A (en) Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application